Efficacy of glofitamab therapy and outcomes
| Parameters . | All patients, n = 70 . | Patients without prior CAR-Ts, n = 20 . | Patients with prior CAR-Ts, n = 50 . | P value . |
|---|---|---|---|---|
| Median time to best response, (range), d | 54 (6-337) | 27 (6-300) | 59 (7-337) | .044 |
| Best response under glofitamab, n (%) | ||||
| ORR, n (%) | 32 (46%) | 6 (30%) | 26 (52%) | .117 |
| CR | 19 (27%) | 2 (10%) | 17 (34%) | .072 |
| PR | 13 (19%) | 4 (20%) | 9 (18%) | 1.000 |
| SD | 6 (9%) | 1 (5%) | 5 (10%) | .666 |
| PD | 31 (44%) | 13 (65%) | 18 (36%) | .035 |
| Median DOR, mo, range | 3.2 (0.4-34) | 2.8 (1.8-11) | 3.6 (0.4-34) | .900 |
| Relapse/PD rate after initiation of glofitamab, n (%) | 47 (67%) | 16 (80%) | 31 (62%) | .172 |
| Median time to relapse/PD after first glofitamab administration, range, y | 60 (6-371) | 27 (6-149) | 75 (7-371) | .064 |
| Reason for ending glofitamab | ||||
| PD | 45 (64%) | 16 (80%) | 29 (58%) | .252 |
| EOT | 9 (13%) | 1 (5%) | 8 (16%) | .430 |
| Hypersensitivity pneumonitis | 1 (1%) | - | 1 (2%) | - |
| Death due to nonlymphoma reason | 3 (4%) | 2 (10%) | 1 (2%) | .226 |
| Consolidation of PR by allo-SCT | 3 (4%) | 1 (5%) | 2 (4%) | 1.000 |
| Ongoing | 9 (13%) | 0 (0%) | 9 (18%) | .052 |
| Median time follow-up from glofitamab initiation, (range), mo | 5 (0.5-35) | 3 (0.5-15) | 5 (0.5-35) | .090 |
| Remission status at last follow-up (available for 69/70 cases) | ||||
| CR | 16 (23%) | 2 (10%) | 14 (29%) | .127 |
| PR | 8 (12%) | 3 (15%) | 5 (10%) | .682 |
| SD | 4 (6%) | 0 (0%) | 4 (8%) | .319 |
| r/r disease | 41 (59%) | 15 (75%) | 26 (53%) | .108 |
| Consolidative therapy after glofitamab | ||||
| Allo-SCT, n (%) | 4 (6%) | 1 (5%) | 3 (6%) | - |
| Survival status at last follow-up | ||||
| Alive | 27 (39%) | 3 (16%) | 24 (55%) | .010 |
| Dead | 43 (61%) | 17 (84%) | 26 (45%) | |
| Mortality reasons | ||||
| r/r lymphoma | 39 (56%) | 15 (75%) | 24 (48%) | .040 |
| Nonlymphoma reasons | 4 (6%) | 2 (10%) | 2 (4%) | .572 |
| Infection | 2 (3%) | 1 (5%) | 1 (2%) | 1.000 |
| Other reasons | 2 (3%) | 1 (5%) | 1 (2%) | .493 |
| Parameters . | All patients, n = 70 . | Patients without prior CAR-Ts, n = 20 . | Patients with prior CAR-Ts, n = 50 . | P value . |
|---|---|---|---|---|
| Median time to best response, (range), d | 54 (6-337) | 27 (6-300) | 59 (7-337) | .044 |
| Best response under glofitamab, n (%) | ||||
| ORR, n (%) | 32 (46%) | 6 (30%) | 26 (52%) | .117 |
| CR | 19 (27%) | 2 (10%) | 17 (34%) | .072 |
| PR | 13 (19%) | 4 (20%) | 9 (18%) | 1.000 |
| SD | 6 (9%) | 1 (5%) | 5 (10%) | .666 |
| PD | 31 (44%) | 13 (65%) | 18 (36%) | .035 |
| Median DOR, mo, range | 3.2 (0.4-34) | 2.8 (1.8-11) | 3.6 (0.4-34) | .900 |
| Relapse/PD rate after initiation of glofitamab, n (%) | 47 (67%) | 16 (80%) | 31 (62%) | .172 |
| Median time to relapse/PD after first glofitamab administration, range, y | 60 (6-371) | 27 (6-149) | 75 (7-371) | .064 |
| Reason for ending glofitamab | ||||
| PD | 45 (64%) | 16 (80%) | 29 (58%) | .252 |
| EOT | 9 (13%) | 1 (5%) | 8 (16%) | .430 |
| Hypersensitivity pneumonitis | 1 (1%) | - | 1 (2%) | - |
| Death due to nonlymphoma reason | 3 (4%) | 2 (10%) | 1 (2%) | .226 |
| Consolidation of PR by allo-SCT | 3 (4%) | 1 (5%) | 2 (4%) | 1.000 |
| Ongoing | 9 (13%) | 0 (0%) | 9 (18%) | .052 |
| Median time follow-up from glofitamab initiation, (range), mo | 5 (0.5-35) | 3 (0.5-15) | 5 (0.5-35) | .090 |
| Remission status at last follow-up (available for 69/70 cases) | ||||
| CR | 16 (23%) | 2 (10%) | 14 (29%) | .127 |
| PR | 8 (12%) | 3 (15%) | 5 (10%) | .682 |
| SD | 4 (6%) | 0 (0%) | 4 (8%) | .319 |
| r/r disease | 41 (59%) | 15 (75%) | 26 (53%) | .108 |
| Consolidative therapy after glofitamab | ||||
| Allo-SCT, n (%) | 4 (6%) | 1 (5%) | 3 (6%) | - |
| Survival status at last follow-up | ||||
| Alive | 27 (39%) | 3 (16%) | 24 (55%) | .010 |
| Dead | 43 (61%) | 17 (84%) | 26 (45%) | |
| Mortality reasons | ||||
| r/r lymphoma | 39 (56%) | 15 (75%) | 24 (48%) | .040 |
| Nonlymphoma reasons | 4 (6%) | 2 (10%) | 2 (4%) | .572 |
| Infection | 2 (3%) | 1 (5%) | 1 (2%) | 1.000 |
| Other reasons | 2 (3%) | 1 (5%) | 1 (2%) | .493 |
Significant P values are set in bold.
Allo-SCT, allogeneic SCT; EOT, end of treatment.